Drug
Psilocybin
Psilocybin: highest development phase Phase 3, developed by Compass Pathways, United Therapeutics. 14 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Compass Pathways, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Psilocybin NCT05624268 | Phase 3 | Treatment Resistant Depression |
| Psilocybin NCT05711940 | Phase 3 | Treatment Resistant Depression |
| Psilocybin NCT06247839 | Phase 3 | Major Depressive Disorder |
| Psilocybin NCT05381974 | Phase 2 | Treatment-Resistant Major Depressive Disorder |
| Psilocybin NCT04433858 | Phase 2 | Treatment Resistant Depression |
| Psilocybin NCT04656301 | Phase 2 | Body Dysmorphic Disorders |
| Psilocybin NCT04661514 | Phase 2 | Anorexia Nervosa |
| Psilocybin NCT04433845 | Phase 2 | Treatment Resistant Depression |
| Psilocybin NCT05312151 | Phase 2 | Post Traumatic Stress Disorder |
| Psilocybin NCT05220410 | Phase 2 | Treatment Resistant Depression |
| Psilocybin NCT05733546 | Phase 2 | Major Depressive Disorder |
| Psilocybin NCT03775200 | Phase 2 | Treatment Resistant Depression |
| Psilocybin NCT04739865 | Phase 2 | Treatment Resistant Depression |
| Psilocybin NCT05481736 | Phase 2 | Anorexia Nervosa |
Latest
No recent events.
Follow Psilocybin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.